Therapy News and Research

RSS

Polyarticular juvenile idiopathic arthritis (PJIA): an interview with Dr. Kramer, VP, Immunology and Infectious Diseases Medical Unit, Genentech

Polyarticular Juvenile Idiopathic Arthritis (PJIA) is a type of Juvenile Idiopathic Arthritis (JIA), a group of Rheumatoid Arthritis (RA) diseases that manifests in multiple ways in children.

3 Jun 2014

Teva Pharmaceutical Industries enters into definitive agreement to acquire Labrys

Teva Pharmaceutical Industries Ltd., and Labrys Biologics, Inc., a privately-held development stage biotechnology company focused on treatments for chronic migraine and episodic migraine, today announced that Teva has entered into a definitive agreement to acquire Labrys, broadening Teva's array of biotechnology assets and capabilities.

3 Jun 2014

Lung cancer patient's blood sample can help predict treatment response

Scientists have shown how a lung cancer patient's blood sample could be used to monitor and predict their response to treatment - paving the way for personalised medicine for the disease.

3 Jun 2014

Eventual drug resistance prevents long-term cure in most patients with metastatic melanoma

A study by scientists in Manchester has shown how melanoma drugs can cause the cancer to progress once a patient has stopped responding to treatment.

3 Jun 2014

Duke researchers identify first piece of new brain-repair circuit

Duke researchers have found a new type of neuron in the adult brain that is capable of telling stem cells to make more new neurons. Though the experiments are in their early stages, the finding opens the tantalizing possibility that the brain may be able to repair itself from within.

3 Jun 2014

New research on innovative immunotherapies for melanoma, cervical cancer presented at ASCO 2014

New research on innovative immunotherapies for advanced or high-risk melanoma and cervical cancer were presented today at the 50th Annual Meeting of the American Society of Clinical Oncology.

3 Jun 2014

Compliance with CPAP therapy may help prevent cardiovascular complications

A new study suggests that continuous positive airway pressure (CPAP) therapy rapidly improves blood pressure and arterial tone in adults with obstructive sleep apnea (OSA).

3 Jun 2014

Nonadherence triples relapse risk in African American and Asian children in remission from ALL

An estimated 25 percent of children in remission from acute lymphocytic leukemia (ALL) are missing too many doses of an essential maintenance medication that minimizes their risk of relapse, according to a study published online today in Blood, the Journal of the American Society of Hematology.

3 Jun 2014

Oncologists urged to consider financial impact of treatments

The American Society of Clinical Oncology is developing a system to rate drugs for advanced cancer based on their likely benefits and side effects, as well as on their price. Meanwhile, better long-term care is urged for the millions who survive the disease and a report details how drugmakers are tailoring treatments to individuals' genetic makeups even though that may affect only small numbers of people.

3 Jun 2014

Enzalutamide drug proves effective in stemming progression of prostate cancer

A drug used to treat men with late-stage prostate cancer proved effective in stemming progression of the disease in research participants who had not yet received chemotherapy and extended their survival, according to results from a multi-national Phase III clinical trial led by the Knight Cancer Institute at Oregon Health & Science University.

3 Jun 2014

Cerenis’ SAMBA and MODE Phase II Studies Meet Primary Endpoints for Treatment of FPHA, HoFH

Cerenis Therapeutics, the biopharmaceutical company, today announced that two of its Phase II studies, SAMBA and MODE (Modifying Orphan Disease Evaluation), with CER-001, an engineered human apoA-I-containing pre-β HDL mimetic, met their primary clinical endpoints in patients with Familial Primary Hypoalphalipoproteinemia (FPHA) and Homozygous Familial Hypercholesterolemia (HoFH), respectively.

2 Jun 2014

ProMark test for prostate cancer meets primary endpoint

Today, for the first time, Metamark presents results from the clinical validation study that showed ProMark, the first and only proteomic-based imaging biopsy test, achieved its primary endpoint by accurately differentiating between aggressive and non-aggressive forms of prostate cancer at early stages of disease.

2 Jun 2014

Ovarian cancer patients with molecular subtypes benefit from bevacizumab

Molecular sequencing could identify ovarian cancer patients who are most likely to benefit from treatment with bevacizumab (Avastin), a Mayo Clinic-led study has found.

2 Jun 2014

First Edition: June 2, 2014

Today's headlines include reports about state health law implementation activities as well as the next steps regarding the difficulties at the VA health system.

2 Jun 2014

$Nektar reports etirinotecan pegol Phase 2 study results in patients with Avastin-refractory high-grade glioma$

Nektar reports etirinotecan pegol Phase 2 study results in patients with Avastin-refractory high-grade glioma

Nektar Therapeutics announced today new data from an investigator-sponsored Phase 2 study of NKTR-102 (etirinotecan pegol) in patients with Avastin-refractory high-grade glioma conducted at Stanford Cancer Institute under the direction of Lawrence Recht, M.D., Professor of Neurology and Neurosurgery, with co-investigator Seema Nagpal, M.D., Clinical Assistant Professor of Neurology and Neurological Sciences, Stanford School of Medicine.

2 Jun 2014

New strategy prolongs survival in men with newly diagnosed, metastatic prostate cancer

Men with newly diagnosed metastatic, hormone-sensitive prostate cancer lived more than a year longer when they received a chemotherapy drug as initial treatment instead of waiting to for the disease to become resistant to hormone-blockers, report scientists from Dana-Farber Cancer Institute and the Eastern Co-operative Oncology Group.

2 Jun 2014

Immune system-boosting therapy slows recurrence of glioblastoma multiforme

A multicenter team of investigators, led by researchers from the Cedars-Sinai Department of Neurosurgery, the Cedars-Sinai Maxine Dunitz Neurosurgical Institute and Dana-Farber Cancer Institute in Boston, have found in a Phase II clinical trial that an immune system-boosting therapy slowed the recurrence of glioblastoma multiforme, or GBM, the most common and deadly malignant brain tumor.

2 Jun 2014

Ibrutinib outperforms ofatumumab as second-line therapy for CLL treatment

In a head-to-head comparison of two Food and Drug Administration-approved drugs for the treatment of relapsed chronic lymphocytic leukemia (CLL), ibrutinib significantly outperformed ofatumumab as a second-line therapy, according to a multicenter interim study published in the OnLine First edition of the New England Journal of Medicine.

2 Jun 2014

Patients with advanced colorectal cancer respond well to new combination therapy

In an aggressive disease known for poor response rates, researchers from The University of Texas MD Anderson Cancer Center found patients with advanced colorectal cancer responded well to a combination therapy of the drugs vermurafenib, cetuximab and irinotecan.

2 Jun 2014

Collaborative research effort produces new genetic insights into brainstem glioma

A collaborative effort between Duke Medicine researchers and neurosurgeons and scientists in China has produced new genetic insights into a rare and deadly form of childhood and young adult brain cancer called brainstem glioma.

2 Jun 2014

Therapy News and Research

Polyarticular juvenile idiopathic arthritis (PJIA): an interview with Dr. Kramer, VP, Immunology and Infectious Diseases Medical Unit, Genentech

Teva Pharmaceutical Industries enters into definitive agreement to acquire Labrys

Lung cancer patient's blood sample can help predict treatment response

Eventual drug resistance prevents long-term cure in most patients with metastatic melanoma

Duke researchers identify first piece of new brain-repair circuit

New research on innovative immunotherapies for melanoma, cervical cancer presented at ASCO 2014

Compliance with CPAP therapy may help prevent cardiovascular complications

Nonadherence triples relapse risk in African American and Asian children in remission from ALL

Oncologists urged to consider financial impact of treatments

Enzalutamide drug proves effective in stemming progression of prostate cancer

Cerenis’ SAMBA and MODE Phase II Studies Meet Primary Endpoints for Treatment of FPHA, HoFH

ProMark test for prostate cancer meets primary endpoint

Ovarian cancer patients with molecular subtypes benefit from bevacizumab

First Edition: June 2, 2014

Nektar reports etirinotecan pegol Phase 2 study results in patients with Avastin-refractory high-grade glioma

New strategy prolongs survival in men with newly diagnosed, metastatic prostate cancer

Immune system-boosting therapy slows recurrence of glioblastoma multiforme

Ibrutinib outperforms ofatumumab as second-line therapy for CLL treatment

Patients with advanced colorectal cancer respond well to new combination therapy

Collaborative research effort produces new genetic insights into brainstem glioma

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News